immune indicator model for predicting efficacy of pd-1 monoclonal antibody

Conditions: Esophageal Squamous Cell Carcinoma; PD-1 Inhibitor

Summary: 200 patients with advanced esophageal cancer who received pd-1 monoclonal antibody treatment would be enrolled in this study. changes in peripheral blood immune cells before and after treatment would be recorded and used for machine learning to establish a prediction model for the efficacy of pd-1 monoclonal antibody treatment.

pd-1 monoclonal antibody has been used as a first-line drug for the treatment of advanced esophageal cancer, however, the ideal predictor of efficacy has not been established. the peripheral immune system plays an important role in driving anti-tumor effects, and the characteristics of peripheral immune cells can predict the effect of pd-1 monoclonal antibody therapy. however, the value of a single indicator for predicting the effect of pd-1 monoclonal antibody therapy is greatly limited. 200 patients with advanced esophageal cancer who received pd-1 monoclonal antibody treatment would be enrolled. changes in peripheral blood immune cells before and after treatment would be recorded and used for machine learning to establish a prediction model for the efficacy of pd-1 monoclonal antibody treatment. the application between the indicator model and the expression level of pd-l1 in tumor tissue in predicting the efficacy of pd-1 monoclonal antibody in advanced esophageal cancer will be also study. this study aims to establish a peripheral blood immune cell-based models to predict the efficacy of pd-1 monoclonal antibody therapy for advanced esophageal cancer, provide a basis for guiding the selection of treatment options for advanced esophageal cancer, and improve the efficacy of pd-1 monoclonal antibody therapy.

Eligibility criteria:
inclusion criteria: * patients with metastatic advanced esophageal squamous cell carcinoma (stage iv) confirmed by histology or cytology who are ready to receive pd-1 monoclonal antibody combined with tp chemotherapy regimen. * eastern cooperative oncology group (ecog) performance status score between 0 and 2. * have measurable lesions. * expected survival \> 3 months. * subjects who have received anti-tumor therapy in the past should be enrolled after the toxicity of the previous treatment has returned to the baseline level (except for residual hair loss effects) or ctcae v4.03 scale score ≤ 1. * female or male subjects of reproductive age and their partners should agree to use effective contraception from the time of signing the icf until 6 months after the last dose of study drug. * absolute neutrophil count (anc) ≥1.5×109/l, platelets ≥100×109/l, hemoglobin ≥9 g/dl. liver: bilirubin ≤1.5 times the upper limit of normal, alkaline phosphatase (ap) , aspartate aminotransferase (ast) and alanine aminotransferase (alt) ≤3.0 times the upper limit of normal (ap, ast, alt ≤5 times the upper limit of normal are allowed if there is liver metastases) renal: calculated creatinine clearance ≥45 ml/min. exclusion criteria: * have active, or have had an autoimmune disease that is likely to recur (eg, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, vasculitis, psoriasis, etc.) or at risk (e.g., organ transplant recipients requiring immunosuppressive therapy). * subjects who need to receive glucocorticoid (prednisone \> 10 mg/day or equivalent dose of other similar drugs) or other immunosuppressive therapy due to certain conditions within 14 days prior to study drug administration. * major surgery, or radical radiation therapy, or palliative radiation therapy within the previous 14 days, or radiopharmaceuticals (strontium, samarium, etc.) within 56 days before starting study treatment. * received systemic anti-tumor therapy, including immunotherapy, biological therapy (tumor vaccines, cytokines, or growth factors to control cancer), etc. 14 days before starting study treatment. * have suffered from interstitial lung disease, chemical pneumonia, hypersensitivity pneumonitis, connective tissue disease pneumonia, pulmonary fibrosis, acute lung disease, etc. (except for local interstitial pneumonia induced by radiotherapy), or uncontrolled systemic disease, including diabetes and hypertension. * patients with human immunodeficiency virus (hiv) infection. * patients with active pulmonary tuberculosis. * any active infection requiring systemic therapy by intravenous infusion within 2 weeks prior to the first dose of study drug. * people who have received a solid organ transplant. * patients who have received any antibody/drug (including anti-programmed death-1 (pd-1), pd-l1, etc.) targeting t-cell co-regulatory proteins (immune checkpoints).